TELA Bio (TELA) Net Cash Flow (2018 - 2026)

TELA Bio's Net Cash Flow history runs 9 years deep, the most recent figure standing at -$11.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 16.23% year-over-year to -$11.3 million in Q1 2026; TTM through Mar 2026 was -$3.2 million, a 154.74% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 million, down 127.45% from the prior year.
• Net Cash Flow retreated to -$11.3 million in Q1 2026 per TELA's latest filing, from $21.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $35.2 million in Q4 2024 and bottomed at -$12.2 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$9.0 million (2024), against an average of -$232058.8.
• Across the five-year window, Net Cash Flow soared 767.96% in 2023 and tumbled 130.4% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$12.2 million in 2022, then climbed by 8.38% to -$11.2 million in 2023, then jumped by 413.55% to $35.2 million in 2024, then tumbled by 39.84% to $21.2 million in 2025, then slumped by 153.28% to -$11.3 million in 2026.
• Per Business Quant, the three latest TELA Net Cash Flow figures stand at -$11.3 million (Q1 2026), $21.2 million (Q4 2025), and -$5.4 million (Q3 2025).